Sumie Koike

1.6k total citations
19 papers, 1.0k citations indexed

About

Sumie Koike is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sumie Koike has authored 19 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 12 papers in Oncology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sumie Koike's work include Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Research Studies (4 papers) and Cancer therapeutics and mechanisms (3 papers). Sumie Koike is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Research Studies (4 papers) and Cancer therapeutics and mechanisms (3 papers). Sumie Koike collaborates with scholars based in Japan, United States and India. Sumie Koike's co-authors include Naoya Fujita, Ryohei Katayama, Tomoko Oh‐hara, Shigeo Sato, Jeffrey A. Engelman, Elizabeth L. Lockerman, Alice T. Shaw, Luc Friboulet, Satoshi Takagi and Miho Takami and has published in prestigious journals such as PLoS ONE, Cancer Research and Oncogene.

In The Last Decade

Sumie Koike

14 papers receiving 996 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sumie Koike Japan 13 669 520 506 199 83 19 1.0k
W. Li China 11 684 1.0× 372 0.7× 337 0.7× 191 1.0× 159 1.9× 47 981
Michael E. Menefee United States 15 610 0.9× 484 0.9× 209 0.4× 181 0.9× 83 1.0× 45 1.3k
Christopher Ruel United States 18 536 0.8× 468 0.9× 309 0.6× 131 0.7× 53 0.6× 47 1.0k
Vladimir Vladimirov United States 12 1.3k 1.9× 235 0.5× 677 1.3× 300 1.5× 62 0.7× 25 1.6k
L Pyle United Kingdom 12 301 0.4× 441 0.8× 359 0.7× 235 1.2× 65 0.8× 18 810
Pooja Ghatalia United States 20 517 0.8× 633 1.2× 653 1.3× 330 1.7× 102 1.2× 81 1.4k
Qinhua Ru United States 9 372 0.6× 616 1.2× 267 0.5× 126 0.6× 117 1.4× 17 939
Bo H. Chao United States 17 872 1.3× 375 0.7× 833 1.6× 205 1.0× 91 1.1× 49 1.3k
Ken Uchibori Japan 15 567 0.8× 360 0.7× 614 1.2× 156 0.8× 64 0.8× 59 885
Sönke Korfee Germany 4 306 0.5× 359 0.7× 273 0.5× 154 0.8× 118 1.4× 8 720

Countries citing papers authored by Sumie Koike

Since Specialization
Citations

This map shows the geographic impact of Sumie Koike's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sumie Koike with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sumie Koike more than expected).

Fields of papers citing papers by Sumie Koike

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sumie Koike. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sumie Koike. The network helps show where Sumie Koike may publish in the future.

Co-authorship network of co-authors of Sumie Koike

This figure shows the co-authorship network connecting the top 25 collaborators of Sumie Koike. A scholar is included among the top collaborators of Sumie Koike based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sumie Koike. Sumie Koike is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Takeuchi, Makoto, et al.. (2025). Osteocyte-like differentiation of osteosarcoma by inorganic phosphate. Differentiation. 146. 100912–100912.
2.
Huang, Tingqin, Satoshi Takagi, Sumie Koike, & Ryohei Katayama. (2025). Inhibition of anti-apoptotic Bcl-2 family members promotes synergistic cell death with ER stress inducers by disrupting autophagy in glioblastoma. Cell Death Discovery. 11(1). 340–340.
3.
Uchibori, Ken, Ai Takemoto, Sumie Koike, et al.. (2024). MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer. Cancer Letters. 604. 217220–217220.
4.
Takagi, Satoshi, Sumie Koike, Miho Takami, et al.. (2024). Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma. Oncogene. 44(12). 794–804.
5.
Yanagitani, Noriko, Sumie Koike, Siew‐Kee Low, et al.. (2022). Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK‐rearranged non–small cell lung cancer. Cancer Science. 113(11). 3888–3900. 8 indexed citations
6.
Shimizu, Yuki, Koutaroh Okada, Jun Adachi, et al.. (2022). GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer. npj Precision Oncology. 6(1). 16–16. 13 indexed citations
7.
Takagi, Satoshi, Sumie Koike, Ai Takemoto, et al.. (2021). Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis. Oncogene. 40(36). 5548–5558. 33 indexed citations
8.
Yoshizawa, Takahiro, Ken Uchibori, Mitsugu Araki, et al.. (2021). Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity. npj Precision Oncology. 5(1). 32–32. 16 indexed citations
9.
Yanagitani, Noriko, Ken Uchibori, Sumie Koike, et al.. (2020). Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms. Cancer Science. 111(3). 932–939. 41 indexed citations
10.
Okada, Koutaroh, Mitsugu Araki, Biao Ma, et al.. (2019). Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. EBioMedicine. 41. 105–119. 87 indexed citations
11.
Sakamoto, Kana, Ryohei Katayama, Reimi Asaka, et al.. (2018). Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. Leukemia. 32(12). 2590–2603. 43 indexed citations
12.
Katayama, Ryohei, Noriko Yanagitani, Sumie Koike, et al.. (2015). Abstract 3590: Resistance mechanisms to ALK inhibitors. Cancer Research. 75(15_Supplement). 3590–3590.
13.
Katayama, Ryohei, Luc Friboulet, Sumie Koike, et al.. (2014). Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib. Clinical Cancer Research. 20(22). 5686–5696. 222 indexed citations
14.
Katayama, Ryohei, Yuka Kobayashi, Luc Friboulet, et al.. (2014). Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer. Clinical Cancer Research. 21(1). 166–174. 147 indexed citations
15.
Takagi, Satoshi, Shigeo Sato, Tomoko Oh‐hara, et al.. (2013). Platelets Promote Tumor Growth and Metastasis via Direct Interaction between Aggrus/Podoplanin and CLEC-2. PLoS ONE. 8(8). e73609–e73609. 170 indexed citations
16.
Nakazawa, Youya, Satoshi Takagi, Shigeo Sato, et al.. (2011). Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti‐Aggrus/podoplanin antibodies. Cancer Science. 102(11). 2051–2057. 48 indexed citations
17.
Misawa, Aya, Ryohei Katayama, Sumie Koike, et al.. (2010). AP-1-Dependent miR-21 Expression Contributes to Chemoresistance in Cancer Stem Cell-Like SP Cells. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 19(1). 23–33. 60 indexed citations
18.
Tanaka, Hiroshi, Yutaka Hoshikawa, Tomoko Oh‐hara, et al.. (2009). PRMT5, a Novel TRAIL Receptor-Binding Protein, Inhibits TRAIL-Induced Apoptosis via Nuclear Factor-κB Activation. Molecular Cancer Research. 7(4). 557–569. 62 indexed citations
19.
Katayama, Ryohei, Sumie Koike, Shigeo Sato, et al.. (2009). Dofequidar fumarate sensitizes cancer stem‐like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP‐mediated drug export. Cancer Science. 100(11). 2060–2068. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by W. Li Breakdown of academic impact, for papers by Michael E. Menefee Breakdown of academic impact, for papers by Christopher Ruel Breakdown of academic impact, for papers by Vladimir Vladimirov Breakdown of academic impact, for papers by L Pyle Breakdown of academic impact, for papers by Pooja Ghatalia Breakdown of academic impact, for papers by Qinhua Ru Breakdown of academic impact, for papers by Bo H. Chao Breakdown of academic impact, for papers by Ken Uchibori Breakdown of academic impact, for papers by Sönke Korfee
Rankless by CCL
2026